What was the market valuation of the US clonorchiasis market in 2024?

The market valuation was $117.6 Million in 2024. Read More

What is the projected market valuation for the US clonorchiasis market by 2035?

The projected valuation for 2035 is $264.69 Million. Read More

What is the expected CAGR for the US clonorchiasis market during the forecast period 2025 - 2035?

The expected CAGR is 7.65% during the forecast period 2025 - 2035. Read More

Which companies are key players in the US clonorchiasis market?

Key players include GSK, Merck & Co, Bayer AG, AbbVie Inc, Pfizer Inc, Sanofi, Novartis AG, and AstraZeneca PLC. Read More

What are the main treatment types in the US clonorchiasis market and their valuations?

Antiparasitic drugs were valued at $158.12 Million, while surgery and supportive care were valued at $53.12 Million and $53.45 Million, respectively. Read More

How do hospitals, clinics, and home care compare as end users in the US clonorchiasis market?

Hospitals accounted for $90.0 Million, clinics for $70.0 Million, and home care for $104.69 Million. Read More

What are the disease stages considered in the US clonorchiasis market?

The disease stages include acute, chronic, and asymptomatic, with valuations of $45.0 Million, $130.0 Million, and $89.69 Million, respectively. Read More

What distribution channels are utilized in the US clonorchiasis market?

Distribution channels include hospital pharmacies at $90.0 Million, retail pharmacies at $120.0 Million, and online pharmacies at $54.69 Million. Read More

How does the market for chronic disease stage compare to acute and asymptomatic stages?

The chronic disease stage is projected to reach $130.0 Million, significantly higher than the acute stage at $45.0 Million and asymptomatic stage at $89.69 Million. Read More

What trends are expected in the US clonorchiasis market as it approaches 2035?

The market is likely to experience growth driven by increasing awareness and advancements in treatment options, with a projected valuation of $264.69 Million by 2035. Read More

US Clonorchiasis Market

US Clonorchiasis Market Research Report By Treatment Type (Antiparasitic Drugs, Surgery, Supportive Care), By End User (Hospitals, Clinics, Home Care), By Disease Stage (Acute, Chronic, Asymptomatic) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.65%

2024 Market Size

$ 117.6 Million

2035 Market Size

$ 264.69 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/18357-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Treatment Type (USD Million)
  1. 4.1.1 Antiparasitic Drugs
  2. 4.1.2 Surgery
  3. 4.1.3 Supportive Care
2. 4.2 Medical Device, BY End User (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Clinics
  3. 4.2.3 Home Care
3. 4.3 Medical Device, BY Disease Stage (USD Million)
  1. 4.3.1 Acute
  2. 4.3.2 Chronic
  3. 4.3.3 Asymptomatic
4. 4.4 Medical Device, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GSK (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer AG (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY END USER
4. 6.4 US MARKET ANALYSIS BY DISEASE STAGE
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 MEDICAL DEVICE, BY END USER, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY END USER, 2024 TO 2035 (USD Million)
16. 6.16 MEDICAL DEVICE, BY DISEASE STAGE, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
18. 6.18 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY END USER, 2025-2035 (USD Million)
  3. 7.2.3 BY DISEASE STAGE, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Clonorchiasis Market Segmentation

US Clonorchiasis Market By Treatment Type (USD Million, 2025-2035)

Antiparasitic Drugs
Surgery
Supportive Care

US Clonorchiasis Market By End User (USD Million, 2025-2035)

Hospitals
Clinics
Home Care

US Clonorchiasis Market By Disease Stage (USD Million, 2025-2035)

Acute
Chronic
Asymptomatic

US Clonorchiasis Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”